Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Paul Goepfert(University of Maryland, Baltimore), Harriet L. Robinson(GeoVax (United States)), David C. Montefiori(Duke University), Marnie Elizaga(Fred Hutch Cancer Center), Georgia D. Tomaras(National Institutes of Health), Laissa Ouedraogo(National Institutes of Health), M. Cardinali(National Institute of Allergy and Infectious Diseases), Spyros A. Kalams(Vanderbilt University Medical Center), Alicia Sato, Yeycy Donastorg, M. Juliana McElrath(Fred Hutch Cancer Center), Lindsey R. Baden(Brigham and Women's Hospital), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), M. C. Keefer(University of Rochester), Javier R. Lama(Asociación Civil Impacta Salud y Educación), Stephen C. DeRosa(Infectious Disease Research Institute), Kelly E. Seaton(International Vaccine Institute)
Cited by 1
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k